Comparison of Side Effects Between 3‐Monthly and 1‐Monthly Paliperidone Palmitate Formulations in Patients With Schizophrenia

20260 citationsJournal Articlehybrid Open Access

Authors

Ilker Ozdemir · Bursa Yuksek Ihtisas Egitim Ve Arastirma Hastanesi

Abstract

In this within-patient cohort stabilized on PP1M, conversion to PP3M was not associated with an increase in overall UKU side-effect burden. Selecting the appropriate dose before switching and preferring monotherapy may enhance treatment comfort. These results may help guide clinicians in selecting long-acting injectable antipsychotics in practice.

Topics & Keywords

Schizophrenia research and treatment Treatment of Major Depression Mental Health and Psychiatry

Publication Details

Published in: Human Psychopharmacology Clinical and Experimental

Volume 41, Issue 1, pp. e70033-e70033

DOI: 10.1002/hup.70033

Field-Weighted Citation Impact: 0.00

Command Palette

Comparison of Side Effects Between 3‐Monthly and 1‐Monthly Paliperidone Palmitate Formulations in Patients With Schizophrenia

Authors

Abstract

Topics & Keywords

Publication Details